Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis
(2024)
Journal Article
Marsh, R., Santos, C. D., Yule, A., Dellschaft, N. S., Hoad, C. L., Ng, C., Major, G., Smyth, A. R., Rivett, D., & van der Gast, C. (2024). Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis. Journal of Cystic Fibrosis, https://doi.org/10.1016/j.jcf.2024.05.002
Background There is a paucity of knowledge on the longer-term effects of CF transmembrane conductance regulator (CFTR) modulator therapies upon the gut microbiome and associated outcomes. In a pilot study, we investigated longitudinal Elexacaftor/Te... Read More about Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis.